Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China · Delayed Price · Currency is CNY 20.27
+0.50 (2.53%)
At close: Mar 6, 2026
Nanjing Vazyme Biotech Revenue
In the year 2025, Nanjing Vazyme Biotech had annual revenue of 1.38B CNY. Nanjing Vazyme Biotech had revenue of 425.48M in the quarter ending December 31, 2025, with 8.54% growth.
Revenue
1.38B
Revenue Growth
-0.00%
P/S Ratio
5.85
Revenue / Employee
480.60K
Employees
2,754
Market Cap
8.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.38B | -16.98K | - |
| Dec 31, 2024 | 1.38B | 91.91M | 7.15% |
| Dec 31, 2023 | 1.29B | -2.28B | -63.97% |
| Dec 31, 2022 | 3.57B | 1.70B | 90.99% |
| Dec 31, 2021 | 1.87B | 304.17M | 19.44% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anhui Huaheng Biotechnology | 2.89B |
| Suzhou Fengbei Biotech Stock | 2.81B |
| Youcare Pharmaceutical Group | 2.45B |
| Chengdu Kanghua Biological Products | 1.21B |
| Jiangxi Fushine Pharmaceutical | 970.32M |
| Wuhan Keqian Biology Co.,Ltd | 950.29M |
| Acrobiosystems | 794.52M |
| Daan Gene | 765.48M |